FDMT — 4D Molecular Therapeutics Share News
0.000.00%
Last trade - 00:00- $710.99m
- $369.25m
- $85.21m
Brief: 4D Molecular Therapeutics Q1 Net Income USD -32.401 Million Vs. IBES Estimate USD -35.8 Million
4D Molecular Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Broadcom, New York Community Bancorp, TopBuild
Brief: 4D Molecular Therapeutics Announces Pricing Of Upsized Public Offering Of Common Stock
Brief: 4D Molecular Therapeutics Announces Proposed Public Offering Of Common Stock
U.S. STOCKS ON THE MOVE-MorphoSys AG, DocuSign, Invitae
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'
U.S. STOCKS ON THE MOVE-Tesla, New York Community Bancorp, GlobalFoundries
U.S. STOCKS ON THE MOVE-Estee Lauder, Nvidia, Everbridge
U.S. STOCKS ON THE MOVE-Cano Health, Boeing, Eli Lilly
4D Molecular gains on interim data from mid-stage study of eye disease drug
U.S. RESEARCH ROUNDUP-Apellis Pharmaceuticals, Saia, Tesla
Brief: 4Dmt Highlights Recent Clinical Pipeline Progress, Near-Term Milestones
Develop Genetic Medicines For Cns Diseases
Brief: 4Dmt Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For 4D-150 Genetic Medicine
U.S. RESEARCH ROUNDUP-Caredx, Ebix, Vera Therapeutics
Brief: 4D Molecular Therapeutics Q3 Net Income USD -10.256 Million
4D Molecular Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview
Brief: 4D Molecular Therapeutics Receives EMA Priority Medicines (Prime) Designation For 4D-150 Clinical-Stage Genetic Medicine For Treatment Of Wet AMD